Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encochleated amikacin - Matinas BioPharma

Next Previous
Drug Profile

Encochleated amikacin - Matinas BioPharma

Alternative Names: Amikacin-LNC; AmK-LNC; C-Amikacin; MAT 2501

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules; Urinary anti-infective agents
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gram-negative infections; Nontuberculous mycobacterium infections

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for phase-I development in Nontuberculous-mycobacterium-infections(In volunteers) in USA (PO)
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (PO)
  • 13 May 2022 Pharmacokinetics and adverse events data from a preclinical trial released by Matinas BioPharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top